<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05132335</url>
  </required_header>
  <id_info>
    <org_study_id>AM05</org_study_id>
    <nct_id>NCT05132335</nct_id>
  </id_info>
  <brief_title>A Repeatability Study of Fatty Acid Uptake Using PET/MR Imaging in Patients With T2DM and Non-diabetic Control Subjects</brief_title>
  <acronym>AM05</acronym>
  <official_title>Assessment of Fatty Acid Uptake and Blood Flow in Tissues Under Fasting and Postprandial Conditions; a Repeatability Study Using Dynamic PET/MR Imaging in Patients With Type 2 Diabetes and Non-diabetic Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Antaros Medical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the overall variation in the assessment of&#xD;
      fatty acid uptake and blood flow in adipose tissue and skeletal muscle in the fasted and&#xD;
      postprandial states by evaluating the repeatability of whole-body three-dimensional kinetic&#xD;
      (4D) combined positron emission tomography and magnetic resonance imaging (PET/MRI) readouts&#xD;
      in participants with type 2 diabetes mellitus (T2DM), and non-diabetic control participants.&#xD;
      Each volunteer participates 4 scanning sessions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of approximately 13 T2DM and 6 control subjects (a total of 19 subjects) are planned&#xD;
      to be enrolled to achieve 11 T2DM and 5 control subjects to complete the study, assuming a&#xD;
      15% drop-out rate. The test-retest repeatability of the ratio of FTHA uptake rates in&#xD;
      subcutaneous adipose tissue (SAT) to skeletal muscle is measured using the intra-class&#xD;
      correlation coefficient (ICC). Assuming an ICC of 0.85, with a 5% two-sided type I error&#xD;
      rate, a sample size of 16 completers will yield approximately 90% power to detect an ICC&#xD;
      statistically significantly greater than 0.4 (usually considered as a criterion for moderate&#xD;
      agreement).&#xD;
&#xD;
      The total radiaooin burden for tshi sitdu yis 27.4 mSv. The study is approved by the local&#xD;
      Ethical committtee and Fimea.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">November 29, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the repeatability of the ratio of subcutaneous adipose tissue (SAT) to skeletal muscle fatty acid uptake rates</measure>
    <time_frame>Baseline through Day 14</time_frame>
    <description>The ratio of SAT to skeletal muscle fatty acid uptake rates</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Experimental: Imaging Biomarkers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each study subject is is studied in four session: twice after overnight fast and twice after liquid meal injestion using PETMRI imaging. Adipose and skeletal muscle pefusion and fatty adic uptake are measured and and the repeability of results tested for these two situations. In PEt studies PET/MRI Scan with radioactive water ([15O]-H2O) and [18F]-FTHA are used as tracers. In this experimental study number of subjects studied is rather small. Therefore volunteers with and without T2 diabetes are analysed together and not on different arms.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging Biomarkers 1</intervention_name>
    <description>Adipose tissue fatty acid uptake in subcutaneous area and intra-abdominal area are measured twice after fasting and twice after meal using a fatty acid tracer 18F-FTHA tracer PETMRI in separate days</description>
    <arm_group_label>Experimental: Imaging Biomarkers</arm_group_label>
    <other_name>Assessment of repeatability of fatty acid uptake in adipose using PETMRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging biomarkers 2</intervention_name>
    <description>Adipose tissue perfusion in subcutaneous area and intra-abdominal area are measured twice after fasting and twice after meal using [15O]-labelled radiowater and PETMRI in separate days</description>
    <arm_group_label>Experimental: Imaging Biomarkers</arm_group_label>
    <other_name>Assessment of repeatability of perfusion in adipose using PETMRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a body mass index (BMI) between 25 to 40 kilograms per meter squared (kg/mÂ²),&#xD;
&#xD;
          -  For participants with a confirmed type 2 diabetes diagnosis: The condition must be&#xD;
             managed either by diet and exercise alone or on a stable dose of metformin&#xD;
&#xD;
          -  For nondiabetic subjects: participants must agree to keep their diet and physical&#xD;
             activity habits stable throughout the study&#xD;
&#xD;
          -  Female participants must be post-menopausal and male participants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Unstable body weight within 30 days prior to screening.&#xD;
&#xD;
          -  For non-diabetic control subjects: evidence of diabetes or prediabetes at screening.&#xD;
&#xD;
          -  Having worked as a metal worker or welder&#xD;
&#xD;
          -  History of alcohol or drug abuse within 5 years of the screening&#xD;
&#xD;
          -  Currently participating, or previous participation in another clinical trial within 30&#xD;
             days prior to the screening visit, or previous participation in another PET imaging&#xD;
             study within 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pirjo R Nuutila, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku PET Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pirjo R Nuutila, MD,PhD</last_name>
    <phone>401626834</phone>
    <phone_ext>+358</phone_ext>
    <email>pirjo.nuutila@utu.fi</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kari Kalliokoski, PhD</last_name>
    <email>kari.kalliokoski@utu.fi</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pirjo R Nuutila, MD, PhD</last_name>
      <phone>401626834</phone>
      <phone_ext>+358</phone_ext>
      <email>pirjo.nuutila@utu.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Turku PET Centre (Turku University Hospital)</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pirjo Nuutila, MD, PhD</last_name>
      <phone>401626834</phone>
      <phone_ext>+358</phone_ext>
      <email>pirjo.nuutila@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Pirjo Nuutila, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>test-retest study, intermediate results not meaningful but the whole data set is reported.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

